A new study published in Nature analysed nearly 28,000 individuals to understand why responses to GLP-1 drugs such as semaglutide vary so widely. Some people lose a significant amount of weight. Others lose very little. Some stop treatment due to side effects. So the question is: why does this happen? Why responses to GLP-1 drugs vary Medications such as tirzepatide act on: appetite blood glucose satiety signals brain pathways (including reward and “food noise”) Yet the resp

In recent years, GLP-1 receptor agonist medications such as Semaglutide and Tirzepatide have revolutionised the treatment of obesity and type 2 diabetes. Beyond improving glycemic control, these drugs induce significant weight loss by reducing appetite, slowing gastric emptying, and improving insulin sensitivity. However, while their effectiveness is well documented, the implications of long-term use deserve deeper consideration . In this article, we explore four aspects that

In recent years, drugs acting on the GLP-1 system  have become central to the treatment of obesity. Originally developed for diabetes, these medications (e.g., Wegovy and Mounjaro) have demonstrated remarkable efficacy in controlling appetite and promoting weight loss. Today, however, research is suggesting something even more intriguing: these drugs might also play a role in reducing the risk of addiction. A recent article published in Nature highlights findings from a larg

GLP-1 and Alzheimer's Disease: The Metabolic Hypothesis of Type 3 Diabetes For many years, Alzheimer’s disease was explained almost exclusively in terms of beta-amyloid plaque accumulation and tau protein tangles. Over the past two decades, however, metabolic research has shifted part of the focus toward another mechanism: impaired insulin signalling in the brain. In 2008, de la Monte and Wands introduced the concept of “type 3 diabetes,” observing that Alzheimer’s brains sh

The landscape of GLP-1 (Glucagon-Like Peptide-1) receptor agonists  is evolving at a breakneck pace. Originally developed for Type 2 diabetes , these drugs have reshaped metabolic medicine and are now at the forefront of obesity, cardiometabolic, and broader therapeutic research . Over the next two years (2026–2028) , we expect dramatic innovation that will redefine how we treat metabolic health. New Drug Modalities & Approvals Oral GLP-1 Receptor Drugs Future— Game Changers

Review of "Fat for Fuel" a book by Joseph Mercola: Fat for Fuel: A Revolutionary Diet to Combat Cancer, Boost Brain Power, and Increase Your Energy One of the most comprehensive guides to the ketogenic diet. Welcome to THE SMART BELLY Blog Enjoy Eating Healthy by Trusting Your Gut Feeling Ketogenic Diet, Cancer Prevention Diet, Brain Cancer Diet The ketogenic diet is very popular these days, and I am often asked for opinions on this radical approach. This diet goes back to D